Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| peripheral blood | 22 studies | 94% ± 10% | |
| lung | 19 studies | 84% ± 18% | |
| brain | 16 studies | 57% ± 15% | |
| intestine | 13 studies | 88% ± 18% | |
| eye | 10 studies | 44% ± 22% | |
| kidney | 9 studies | 71% ± 24% | |
| liver | 7 studies | 53% ± 24% | |
| bone marrow | 6 studies | 75% ± 34% | |
| heart | 6 studies | 39% ± 17% | |
| pancreas | 5 studies | 67% ± 22% | |
| lymph node | 5 studies | 98% ± 2% | |
| uterus | 5 studies | 94% ± 9% | |
| prostate | 5 studies | 65% ± 35% | |
| adipose | 4 studies | 59% ± 28% | |
| esophagus | 4 studies | 68% ± 23% | |
| placenta | 4 studies | 48% ± 23% | |
| skin | 4 studies | 82% ± 23% | |
| breast | 4 studies | 92% ± 5% | |
| stomach | 3 studies | 65% ± 22% | |
| thymus | 3 studies | 72% ± 38% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| lung | 100% | 128603.58 | 578 / 578 | 100% | 2900.06 | 1155 / 1155 |
| uterus | 100% | 74028.63 | 170 / 170 | 100% | 3061.99 | 459 / 459 |
| bladder | 100% | 56990.29 | 21 / 21 | 99% | 3177.39 | 500 / 504 |
| stomach | 100% | 64026.03 | 359 / 359 | 99% | 2561.20 | 283 / 286 |
| ovary | 100% | 51090.47 | 180 / 180 | 99% | 2125.80 | 425 / 430 |
| breast | 100% | 91368.36 | 459 / 459 | 99% | 2234.42 | 1103 / 1118 |
| intestine | 99% | 60842.84 | 952 / 966 | 100% | 2982.61 | 526 / 527 |
| prostate | 99% | 50346.36 | 243 / 245 | 98% | 1127.16 | 490 / 502 |
| kidney | 99% | 54302.02 | 88 / 89 | 98% | 1995.89 | 880 / 901 |
| brain | 96% | 53195.78 | 2542 / 2642 | 99% | 2600.99 | 701 / 705 |
| esophagus | 99% | 54859.47 | 1427 / 1445 | 96% | 1478.98 | 176 / 183 |
| adrenal gland | 100% | 70998.09 | 258 / 258 | 94% | 1388.93 | 216 / 230 |
| thymus | 97% | 35934.33 | 633 / 653 | 96% | 2475.75 | 583 / 605 |
| pancreas | 74% | 18814.44 | 244 / 328 | 98% | 3299.29 | 174 / 178 |
| skin | 99% | 63321.69 | 1783 / 1809 | 72% | 1060.24 | 342 / 472 |
| liver | 45% | 9879.02 | 101 / 226 | 75% | 1017.16 | 305 / 406 |
| adipose | 100% | 124269.51 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 7605.29 | 29 / 29 |
| spleen | 100% | 156041.24 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 2025.50 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 3234.58 | 1 / 1 |
| blood vessel | 100% | 93759.61 | 1331 / 1335 | 0% | 0 | 0 / 0 |
| peripheral blood | 100% | 201856.50 | 926 / 929 | 0% | 0 | 0 / 0 |
| heart | 90% | 30527.80 | 777 / 861 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 21% | 187.16 | 17 / 80 |
| muscle | 14% | 2919.05 | 110 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_1905273 | Biological process | positive regulation of proton-transporting ATP synthase activity, rotational mechanism |
| GO_0043536 | Biological process | positive regulation of blood vessel endothelial cell migration |
| GO_0042989 | Biological process | sequestering of actin monomers |
| GO_0050728 | Biological process | negative regulation of inflammatory response |
| GO_0030334 | Biological process | regulation of cell migration |
| GO_2001028 | Biological process | positive regulation of endothelial cell chemotaxis |
| GO_2001171 | Biological process | positive regulation of ATP biosynthetic process |
| GO_0007015 | Biological process | actin filament organization |
| GO_0033209 | Biological process | tumor necrosis factor-mediated signaling pathway |
| GO_0043124 | Biological process | negative regulation of canonical NF-kappaB signal transduction |
| GO_0005856 | Cellular component | cytoskeleton |
| GO_0005576 | Cellular component | extracellular region |
| GO_0005829 | Cellular component | cytosol |
| GO_0031093 | Cellular component | platelet alpha granule lumen |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0005634 | Cellular component | nucleus |
| GO_0019899 | Molecular function | enzyme binding |
| GO_0003785 | Molecular function | actin monomer binding |
| GO_0003723 | Molecular function | RNA binding |
| GO_0140311 | Molecular function | protein sequestering activity |
| GO_0005515 | Molecular function | protein binding |
| Gene name | TMSB4X |
| Protein name | TMSB4X protein Thymosin beta-4 Thymosin beta Thymosin beta-4 (T beta-4) (Fx) [Cleaved into: Hemoregulatory peptide AcSDKP (Ac-Ser-Asp-Lys-Pro) (N-acetyl-SDKP) (AcSDKP) (Seraspenide)] |
| Synonyms | TMSB4 THYB4 TB4X hCG_1646598 |
| Description | FUNCTION: Plays an important role in the organization of the cytoskeleton . Binds to and sequesters actin monomers (G actin) and therefore inhibits actin polymerization . .; FUNCTION: [Hemoregulatory peptide AcSDKP]: Potent inhibitor of bone marrow derived stem cell differentiation . Acts by inhibits the entry of hematopoietic pluripotent stem cells into the S-phase (By similarity). . FUNCTION: Plays an important role in the organization of the cytoskeleton. Binds to and sequesters actin monomers (G actin) and therefore inhibits actin polymerization. . |
| Accessions | ENST00000380635.5 ENST00000451311.7 ENST00000380636.1 Q0P5P4 Q0P5U7 Q0P5N8 Q0P5T0 P62328 Q0P5Q0 A2VCK8 ENST00000380633.1 |